Literature DB >> 25100817

Performance comparison of the versant HCV genotype 2.0 assay (LiPA) and the abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6.

Ruifeng Yang1, Xu Cong1, Shaocai Du1, Ran Fei1, Huiying Rao1, Lai Wei2.   

Abstract

The Versant HCV genotype 2.0 assay (line probe assay [LiPA] 2.0), based on reverse hybridization, and the Abbott Realtime HCV genotype II assay (Realtime II), based on genotype-specific real-time PCR, have been widely used to analyze hepatitis C virus (HCV) genotypes. However, their performances for detecting HCV genotype 6 infections have not been well studied. Here, we analyzed genotype 6 in 63 samples from the China HCV Genotyping Study that were originally identified as genotype 6 using the LiPA 2.0. The genotyping results were confirmed by nonstructural 5B (NS5B) or core sequence phylogenetic analysis. A total of 57 samples were confirmed to be genotype 6 (51 genotype 6a, 5 genotype 6n, and 1 genotype 6e). Four samples identified as a mixture of genotypes 6 and 4 by the LiPA 2.0 were confirmed to be genotype 3b. The remaining two samples classified as genotype 6 by the LiPA 2.0 were confirmed to be genotype 1b, which were intergenotypic recombinants and excluded from further comparison. In 57 genotype 6 samples detected using the Realtime II version 2.00 assay, 47 genotype 6a samples were identified as genotype 6, one 6e sample was misclassified as genotype 1, and four 6a and five 6n samples yielded indeterminate results. Nine nucleotide profiles in the 5' untranslated region affected the performances of both assays. Therefore, our analysis shows that both assays have limitations in identifying HCV genotype 6. The LiPA 2.0 cannot distinguish some 3b samples from genotype 6 samples. The Realtime II assay fails to identify some 6a and all non-6a subtypes, and it misclassifies genotype 6e as genotype 1.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25100817      PMCID: PMC4187793          DOI: 10.1128/JCM.00882-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  43 in total

1.  A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes.

Authors:  Carla Kuiken; Christophe Combet; Jens Bukh; Tadasu Shin-I; Gilbert Deleage; Masashi Mizokami; Russell Richardson; Erwin Sablon; Karina Yusim; Jean-Michel Pawlotsky; Peter Simmonds
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

2.  [Hepatitis C virus genotyping: comparison of the Abbott RealTime HCV Genotype II assay and NS5B sequencing].

Authors:  P Vaghefi; E Marchadier; E Dussaix; A-M Roque-Afonso
Journal:  Pathol Biol (Paris)       Date:  2009-11-25

3.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

Review 4.  Directly acting antivirals against hepatitis C virus.

Authors:  Vincent Soriano; Eugenia Vispo; Eva Poveda; Pablo Labarga; Luz Martin-Carbonero; Jose Vicente Fernandez-Montero; Pablo Barreiro
Journal:  J Antimicrob Chemother       Date:  2011-06-07       Impact factor: 5.790

5.  Second-generation line probe assay for hepatitis C virus genotyping.

Authors:  L Stuyver; A Wyseur; W van Arnhem; F Hernandez; G Maertens
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

6.  The epidemic behavior of the hepatitis C virus.

Authors:  O G Pybus; M A Charleston; S Gupta; A Rambaut; E C Holmes; P H Harvey
Journal:  Science       Date:  2001-06-22       Impact factor: 47.728

7.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

8.  Determining hepatitis C genotype by analyzing the sequence of the NS5b region.

Authors:  K Sandres-Sauné; P Deny; C Pasquier; V Thibaut; G Duverlie; J Izopet
Journal:  J Virol Methods       Date:  2003-05       Impact factor: 2.014

9.  Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource.

Authors:  Donald B Smith; Jens Bukh; Carla Kuiken; A Scott Muerhoff; Charles M Rice; Jack T Stapleton; Peter Simmonds
Journal:  Hepatology       Date:  2014-01       Impact factor: 17.425

10.  222 base pairs in NS5B region and the determination of hepatitis C virus genotype 6.

Authors:  Teeraporn Chinchai; Suwanna Noppornpanth; Kavita Bedi; Apiradee Theamboonlers; Yong Poovorawan
Journal:  Intervirology       Date:  2006-02-16       Impact factor: 1.763

View more
  13 in total

Review 1.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

2.  Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6.

Authors:  Karin S Ku; Ramakrishna K Chodavarapu; Ross Martin; Michael D Miller; Hongmei Mo; Evguenia S Svarovskaia
Journal:  J Clin Microbiol       Date:  2016-05-04       Impact factor: 5.948

3.  Hepatitis C Virus Genotype Analyses in Chronic Hepatitis C Patients and Individuals With Spontaneous Virus Clearance Using a Newly Developed Serotyping Assay.

Authors:  Ruifeng Yang; Xiqin Yang; Bingshui Xiu; Huiying Rao; Ran Fei; Wenli Guan; Yan Liu; Qian Wang; Xiaoyan Feng; Heqiu Zhang; Lai Wei
Journal:  J Clin Lab Anal       Date:  2016-06-13       Impact factor: 2.352

4.  Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study.

Authors:  Su Rin Shin; Young Seok Kim; Young-Seok Lim; June Sung Lee; Jin Woo Lee; Sun Myung Kim; Sook-Hyang Jeong; Joo Hyun Sohn; Myung Seok Lee; Sang Hoon Park
Journal:  Gut Liver       Date:  2017-03-15       Impact factor: 4.519

5.  Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes.

Authors:  Shrikant Dashrath Warkad; Satish Balasaheb Nimse; Keum-Soo Song; Taisun Kim
Journal:  ACS Omega       Date:  2020-05-08

Review 6.  HCV Detection, Discrimination, and Genotyping Technologies.

Authors:  Shrikant Dashrath Warkad; Satish Balasaheb Nimse; Keum-Soo Song; Taisun Kim
Journal:  Sensors (Basel)       Date:  2018-10-12       Impact factor: 3.576

7.  A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?

Authors:  Rui-Feng Yang; Yan Liu; Cai-Yan Zhao; Ya-Xing Ding; Yu Chen; Ya-Dong Wang; Zhong-Ping Duan
Journal:  PLoS One       Date:  2019-02-12       Impact factor: 3.240

8.  Evaluation of the Abbott Real Time HCV genotype II assay for Hepatitis C virus genotyping.

Authors:  Fatma Mutlu Sariguzel; Elife Berk; Selma Gokahmetoglu; Baris Derya Ercal; Ilhami Celik
Journal:  Pak J Med Sci       Date:  2015 Sep-Oct       Impact factor: 1.088

9.  Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district.

Authors:  Ennio Polilli; Valeria Cento; Umberto Restelli; Francesca Ceccherini-Silberstein; Marianna Aragri; Velia Chiara Di Maio; Antonina Sciacca; Fiorenzo Santoleri; Paolo Fazii; Alberto Costantini; Carlo Federico Perno; Giustino Parruti
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-14

10.  Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples.

Authors:  Shrikant Dasharath Warkad; Satish Balasaheb Nimse; Keum-Soo Song; Wasun Chantratita; Viroj Pongthanapisith; Laxman Uddhav Nawale; Taisun Kim
Journal:  Virol J       Date:  2018-07-11       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.